Mark Selby

Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA.

ARCH Venture Partners LLC is a Venture Capital firm founded in 1986. The firm is headquartered in Chicago with additional office in Dublin.

Roche Pharmaceuticals provides research and development services in the fields of pharmaceuticals and diagnostics. It also provides diagnostics and drugs for cancer and transplantation. The company is headquartered in Nutley, NJ.

TempestTx, Inc. is a clinical stage biotechnology company which engages in advancing small molecule therapeutics that modulate anti-tumor pathways. The company is headquartered in South San Francisco, CA.

Vivace Therapeutics, Inc. discovers and develops novel cancer drug. The company was founded by Shuang Qiao in 2014 and is headquartered in San Mateo, CA.

Harvard University engages in the provision of teaching and research. It has twelve degree-granting Schools in addition to the Radcliffe Institute for Advanced Study, offering a global education. The university was founded in 1636 and is headquartered in Cambridge, MA.

University of Washington functions as a College/University. The company is headquartered in Seattle, WA.

Peking University provides post-secondary education services. It offers undergraduate and graduate courses. It provides courses such as basic and applied sciences, social sciences and the humanities, sciences of medicine, management, and education. The company was founded by JiaNai Sun in 1898 and is headquartered in Beijing, China.

Northwestern University is a private institution founded in 1851 to serve the Northwest Territory, an area that now includes the states of Ohio, Indiana, Illinois, Michigan, Wisconsin and parts of Minnesota. Northwestern has three campuses

Novartis Vaccines & Diagnostics, Inc. manufactures and markets health care and nutritional products. The company was founded in 1986 and is headquartered in East Hanover, NJ.

Modernatx, Inc. develops messenger RNA therapeutics. Its vivo drug technology that produces human proteins, antibodies and entirely novel protein constructs inside patient cells, which are in turn secreted or active intracellularly. The company was founded by Derrick J. Rossi, Doug G. Cole, Doug G. Cole, Robert S. Langer, Jr., Noubar Afeyan, and Kenneth R. Chien in 2011 and is headquartered in Cambridge, MA.

NanoCellect Biomedical, Inc. develops flow cytometry and cell sorting technology solutions for life science researchers to perform cellular analysis, develop molecular diagnostics, and improve personalized medicine. Its products include wolf cell sorter and N1 single cell dispenser. The company was founded by Nate Heintzman and Yuhwa Lo in 2009 and is headquartered in San Diego, CA.

eTheRNA immunotherapies NV develops novel immunotherapies to overcome cancers and infectious diseases. The company was founded by Carlo Heirman, Kris Thielemans and Sonja van Meirvenne in January 21, 2013 and is headquartered in Niel, Belgium.

IIF Management Co LLC (Illumina Ventures) is a venture capital firm founded in 2015 by Nicholas J. Naclerio. The firm is headquartered in Foster City, California.

Part of Thermo Fisher Scientific, Inc., Life Technologies International BV manufactures analytical instruments.

Arbor Biotechnologies, Inc. engages in curating genetic biodiversity and discover novel protein functions from nature. The company was founded by David Arthur Svott, Winston Xia Yan, Feng Zhang and David R. Walt in 2016 and is headquartered in Cambridge, MA.

Evox Therapeutics Ltd. develops and markets transformational therapeutics. The firm creates novel exosome-based biotherapeutics for the treatment of various severe diseases with limited options for patients and their families. The company was founded by Matthew Wood, Per Lundin, and Samir EL Andaloussi in 2016 and is headquartered in Oxford, the United Kingdom.

The Cardiovascular Research Institute operates a cardiovascular research institute. The American company was founded by Alison Schecter.

Actym Therapeutics, Inc. engages in development of novel immuno-oncology therapies. The company was founded by Christopher D. Thanos and Laura Hix Glickman and is headquartered in Berkeley, CA.

Chimeron Bio Corp. is a biotechnology company based in the USA that is focused on developing a pipeline of products in oncology, rare genetic disorders, and infectious diseases using its proprietary chaesar™ platform. The American company is researching self-amplifying RNA (sRNA) to develop novel RNA drugs and vaccines for various diseases. Chimeron Bio is combining a first-in-class platform and the science of synthetic genomics to develop a robust portfolio of self-amplifying RNA therapeutics. The company was founded by Jolly Mazumdar, and the CEO is Kevin J. Heyeck.

Totus Medicines, Inc. manufactures drug products. The company is based in Cambridge, MA. The company was founded by Neil Dhawan, Jason Pontin. Neil Dhawan has been the CEO since incorporation.

Incendia Therapeutics, Inc. develops a novel class of anti-cancer therapies. The company is based in Boston, MA. The company was founded in 2003 by Laurent Audoly, Colin Glenn Begley, Olga Granaturova, Guy Travis Clifton. Laurent Audoly has been the CEO since 2003.

Opna Bio is a clinical-stage biopharmaceutical company located in the US that focuses on discovering and developing novel oncology therapeutics. Opna's lead clinical compound, opn-2853, a bromo and extra terminal (bet) domain inhibitor, is currently in a phase 1/2 trial with ruxolitinib (jakafi®) in myelofibrosis, a chronic bone marrow disorder. The American company's team has a proven track record of scientific expertise and commercial value creation, having advanced multiple FDA-approved drugs to market. The company has a broad portfolio that targets multiple drivers of cancer, including a novel oncology discovery program focused on the fragile-x mental retardation protein (fmrp) and a diversified pipeline of validated oncology assets acquired from plexxikon.